Engineering Conferences International

ECI Digital Archives
Single-Use Technologies V: Building The Future

Proceedings

3-23-2022

Addressing the pain-points of single-use intensified multi-product
downstream and liquid processing in a dancefloor production
room layout
Stuart Tindal
Ganesh Kumar
Fritjof Linz
Michael Koch
Fabien Rousset

See next page for additional authors

Follow this and additional works at: https://dc.engconfintl.org/sut_v

Authors
Stuart Tindal, Ganesh Kumar, Fritjof Linz, Michael Koch, Fabien Rousset, David Johnson, Franziska
Froboese, and Geert Lissens

De fining a Sustainable Te chnology Roadmap in Re sponse to Re al-Life
Custome r Expe rie nce s for Inte nsifie d Downstre am Proce sse s
Stuart Tindal, Gane sh Kumar, Franziska Froboe se , Martin Lobe dann, David Johnson 2 , Michae l Koch 3 , Ge e rt Lisse ns 4 , Fritjof Linz, Fabie n Rousse t 5 ,
1 Sartorius

Ste dim Biote ch GmbH, 2. Sartorius Ste dim Chromatography Syste ms Ltd 3. Sartorius Ste dim Syste ms GmbH 4. Sartorius Be lgium N.V. 5. Sartorius Ste dim France SAS.
Corre sponding author: stuart.tindal@sartorius.com

Pain e valuation
score

The sales of biologics reached over 505 billion in 2020 and the market continues to have accelerated double
- digit growth
unde r the CO VID-19 burde n, thus biopharmace utical companie s continue to pipe line biologics for a mounting global
patie nt base . Ne ve rthe le ss, biologics are changing, and the ne e ds of the ir manufacturing are changing with the m.
Eme rging biologics (e .g., antibody–drug conjugate s, viral ve ctors, mRNA, bi/multi-spe cifics) are coming with comple x or
le an manufacturing re quire me nts. Additionally, the global marke t is se arching for more affordable & sustainable biologics
and biosimilars, cre ating an incre asingly compe titive space within the e me rging countrie s who se e k to manufacture
locally.
The BioPhorum O pe rations Group (BPO G), a cross-industry organization of biopharmace utical e nd use rs and supplie rs,
colle cte d biopharmace utical industry drive rs stating:
 90 % re duction in capital e xpe nditure (CAPEX) and manufacturing costs in the ne xt de cade .
 re duce product change ove r time s by 90 % to improve re sponse s to variability in de mand
 drive down ne w facility build time s by 70 %
The que stion is, how doe s this translate to actionable and prioritize d points of improve me nt for a biological imple me nte r &
supplie r to work on?
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Figure 1: infinite cyclic proce ss of de sign thinking me thod
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Increase Efficiency

Lower GOGS

Reduce Footprint

Inte nsifie d, standalone unit ope ration incre ase s the individual ste p productivity or e fficie ncy.

level 2

Conne cted proce ss: subse que nt proce ss ste ps start be fore first ste p is finishe d; software orche stration is be ne ficial,
min. 2 ste ps; fits for batch &pe rfusion USP; could be stagge re d batch; may have pooling tanks; might be calle d
cluste re d or linke d proce ss

level 3

Continuous process: special, more integrated case of a connected process with steady state flow; software
orchestration is a must have; predominantly for perfusion USP; only small intermediate (surge) tanks; might be named
semi-continuous or pseudo-continuous

level 3.1

Flow-through continuous proce ss: furthe r inte grate d case with comple te ste ady state flow. All bind and e lute ste ps
are re place d with flow through mode . Mole cule doe s not stop – impuritie s are re move d from stre am

Upstream scenario
USP type
Titer (nominal), duration
Productivity

Scenario 1

Scenario 2

Scenario 3

Scenarios 4

2 kL Standard
Fed batch

2 kL High Inoculation
Fed Batch

2 kL Concentrated
Fed Batch

500 L
Perfusion

5 g/L, 12 d
0.4 g/L/d

8 g/L, 12 d
0.7 g/L/d

15 g/L, 14 d
1.1 g/L/d

Cell removal & Clarification
output

2,000 L
10,000 g @ 5 g/L

2,000 L
16,000 g @ 8 g/L

2,000 L
30,000 g @ 15 g/L

6,000 L @ 1vvd
13,200 g @ 2.2 g/L

Step duration
Capture
& Polishing 1+2 type

Batch, single device
FT + B&E

Empathy Mapping

Viral inactivation

Batch, mixing tanks

Dual mixing tanks

Batch,
Low bioburden

Batch,
Low bioburden

Batch,
Low bioburden

200 kg/a

300 kg/a

500 kg/a

DSP Intensification level

Put on the use r’s shoe s and imagine yourse lf in the conte xt of that journe y. A simple but ve ry e ffe ctive tool to pe rce ive
what the use rs is fe e ling and pe rhaps thinking. Map out what the use r says, doe s, fe e ls or things while journe ying along the
sce nario map. Eve ntually the map will sharpe n the aware ne ss of use r’s vie w, (conce rns & be ne fits) and he lp align the
busine ss and de ve lopme nt activitie s.

Virus removal,
concentration, & buffer
exchange
DSP Line Output

O bse rve d – Pain point mapping
Pain points we re cluste re d & de taile d out from a pane l of initial use r inte rvie ws (n =28) utilizing as-is- sce nario te chnique .
Fre que nt why, who what, whe n & whe re que stions e nable d cate gorization within ce rtain pain-points but 17 made it to the
final map (table 2), analysis (Figure 2) and contribute d to the proble m state me nt
Difficult to
Handle

Fe ar of Le akage s &
failure s

Lack of
Automation

Lack of e asy IT &
le ak te st
capability

Poor Se nsoring /
Se nsor
Pe rformance

Too big /
Cle anroom
De mand

Lack of de tail and
consiste ncy in
Q ualification /
Docume ntation

Challe nging
Scalability /
Volume /
Proce sse s
Transfe r

High CAPEX,
O PEX &GoGs

Poor che mical
compatibility or
mate rial stability

Long Re sponse - /
Le ad Time s

Lack of
Standardization
that can re duce #
of SU Ite ms

2.2 g/L @ 1vvd – 12 d (max.
60 d), 2.2 g/L/d

Midstream

We listened to real operators in batch downstream processing in their 8- hour shift to know what needs to be done for
the subsequent shift and we heard from their managers and their concerns & challenges of 24
- hour batch processing.
In addition, we considered:
 Product Journey of a SU instrument or a SU consumable from user request– our production/assembly to user arrival
to in-process usage and end of product life
 Information flow – Engineering technical document package for the Common technical documentation submission
/ Business rational to conceptual process modelling / facility layout & capacity planning

None or level 1

Level 2

Level 2

Level 3

~1-2 shift

~1-2 shifts

~2 shifts

12 days

Dual device w/o overloading Multi device with overloading
FT + B&E
2x FT
Low pH

Multi device, with overloading
/ parallel batch 2x FT

Photonic

Inline (inflow),
continuous VI
Conti,
closed processing
(zero bioburden)
160 kg/a
(650 kg/a @ 2kL)

Table 3: outlines the intensification scenarios of both upstream and downstream. Additional, how a batch or continuous upstre
am flow feeds into a
batch, connect or continuous downstream . Scenario 1/2/3 are not mutually exclusive to the downstream intensification levels
which aim to
debottleneck the relevant purification steps to increase efficiency, reduce footprint or lower the cost contribution.

Discussion and Future O utlook

Ke y conce rn or pain points to come out of the study; e fficie ncy, simplicity & sustainability (e conomic & e cological)


O ve r
De pe nd e ncy on
O ne Supplie r
(AO S)

How can I go faste r but not risk my proce ss? Highe r le ve ls of orche stration, re duce both the downtime & fre que ncy of
turnarounds , incre ase consumable compatibility to more SU syste m, safe robust n/outle ts conne ctions, sustainability of
consumable s, non-product contact mate rials, primary and se condary packaging



What happe ns if one SU compone nt is broke n? – de te ction and risk to the inte grity of the proce ss , balance the costs of
product with what will I ge t out of my use .

Low Sustainability
/ Waste
Manage me nt

Following the se Bioproce ssing tre nds, growth and comme rcial busine ss drive rs the rise of inte nsifie d downstre am
proce ssing amplify the de mands on single -use te chnology. hills like ;

Table 2: bre ak down of se gme nts & pe rsona pains

Re fle ct – Pain point analysis

1.8

Make - Bioprocess intensification scenario mapping

Quality Assurance &
Management

We created these 4 key personas (table 4) within our user base. We gave them names and personalities then journeyed
them through a day or for the duration of a SU facility project. We took their perceptions, benefit and concerns into
empathy mapping, and drafted the first pain points into an initial map .

Difficult to
Conne ct to
highe r
Automation
structure s

1.9

Downstream process intensification levels

Table 1: list the 4 key personas created to reflect on the pain points in SU downstream production

Lack of
Harmonize d
Industrial
Standard
Conne ction

1.9

Going by the thought process of ‘get more out of what I have– or build something where I can get
more in less time or in less space’ from a customer standpoint, the following represent the hills/
obstacles which a customer must consider when intensifying upstream:
 Upstream PI [table 3; Scenario 2 & 3] means higher bioreactor output and drives the need for more
efficient DSP. DSP steps need to go faster, more forceful or bigger to process the material in same
time to retain the facility working shift structure an minimize the impact of the existing equipment &
infrastructure.
 Upstream PI [table 3 scenario 4] feeds the need for continuous downstream manufacturing as the
outward flow rate needs to match the downstream processing rate. This is likely to extend to weeks
or possible months of constant processing time.
Ultimately the future facility aims to increase the space time yield of its product(s) while reducing cost
of good and decreasing the facility footprint.

A pe rsona is a fictional characte r that re pre se nts a ce rtain group of pe ople . The pe rsona comprise s the characte ristic,
be haviors, wishe s, fe ars, habits & cultural backgrounds of this particular use r type . Thus, to gain a de e pe r insight of the use r
and ide ntify the re le vant proble ms and ne e ds we cre ate d 4 pe rsonas for SU downstre am proce ssing.

Supply Chain
Comple xity

2.0

Customer hills (intensification)

Pe rsona & As-Is-Sce nario approach

Operators & operator Technical Single-use
managers
/ process managersengineers

1.6

4.0

Figure 2: Q uantitative Pain point inte nsity mapping of pe rce ive d challe nge s of SU downstre am proce ssing. All re gions, all pe rsonas & all se gme nt groups
n=47 – 5 was the most inte nse ly fe lt pain, 0 was no pain.

De sign Thinking Me thods:

The first step is to get to know your user(s)….

2.0

StdDev Evaluation

Low pain 1.0

With this ge ne ral ne e d in mind, combining De sign Thinking me thodology and insights from single -use biological
manufacturing use rs we re gathe re d through an e xte nde d surve y with ke y biopharma industry companie s and institute s
re pre se nting the various use r groups. All inte rvie we e re sponse s we re populate d, to e nable the cate gorization and sorting
of distinct use r pe rce ptions of like s, pain-points, and be ne fits. The outcome of the activity was the starting point to de fine
what are the critical compone nts for a sustainable te chnology roadmap to addre ss the ne e ds for the rapidly inte nsifying
biologics manufacturing marke t.

The objective is useability.
To ask & listen, to watch & learn, to handover and let the user use their
intuition & interaction. Reflecting on the gathered information,
grouping & filtering, prioritizing & sorting. With this, the beginning of
the ideation starts with the key question “how might I help this user”.
Switching between focus mind states and creative flow, iterate the
ideas, test how they work and ask the user for feedback. Only within this
modus can we assured to emergence of customer validated solutions.

Evaluation

Pain distribution

Introduction

High pain 5.0

Xoxxo

Looking at the whole datase t (figure X) te lls a single story of the pe rce ive d pain across the 47 inte rvie we d use rs' pe rsonas
from around the world. From the highe st fe lt pain “lack of standardization of single use te chnology” to the te chnologie s
be ing “too big or not suitable for the cle anroom” all have an impact to the diffe re nt use r groups. Whe n using cate gory
filte rs or linking principal compone nts analysis (PCA) we can dig into the statistics and se e furthe r tre nds and groupings.
Not all pain is fe lt to the same inte nsity by e ach pe rsona, re gion or se gme nt.

Conclusion Proble m State me nt


re ducing the risk of le akage , contamination & failure whe re the re are highe r driving force s, longe r proce ss duration &
more conne ctions points



de cre asing # and/or volume of static points (surge bags) and conne cting ste ps in-line for a continuous proce ss flow



e asing ope rator handling, while minimizing use r e rror risk as comple xity incre ase s ove r multiple conne cte d proce ss
ste ps and highe r de gre e s of proce ss control & automation orche stration



growing mate rial / de sign comple xity/fle xibility and more compre he nsive variant manage me nt



ratifying the re duction of e conomic and e cological impact of single -use proce sse s

Innovation single use flow kit, se nsor, actuator & conne ctivity te chnologie s to e nable a ne w ge ne ration of consumable &
single use syste ms

